ResearcherCapital Medical UniversityNo recent work listed
Xingmao Zhang
Matched on ORCID iD 0000-0002-4946-1102; OpenAlex author ID A5060770482. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper
Papers 3
- ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1. Co-author DOI 10.1038/s41389-022-00418-2↗
- Reconstructing spleno-mesenterico-portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer-a feasible method to avoid left-sided port… Co-author DOI 10.1002/cam4.4093↗
- Risk factors related to metastasis of para-aortic lymph nodes in pancreatic ductal adenocarcinoma: A retrospective observational study. Co-author DOI 10.1097/md.0000000000012370↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hua Fan · 3 shared papers, 2018–2022 · strength 0.43
- Paper Reconstructing spleno-mesenterico-portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer-a … DOI 10.1002/cam4.4093↗
- Paper ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1. DOI 10.1038/s41389-022-00418-2↗
- Paper Risk factors related to metastasis of para-aortic lymph nodes in pancreatic ductal adenocarcinoma: A retrospective obse… DOI 10.1097/md.0000000000012370↗
- Qiang He · 2 shared papers, 2018–2021 · strength 0.28
- Paper Reconstructing spleno-mesenterico-portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer-a … DOI 10.1002/cam4.4093↗
- Paper Risk factors related to metastasis of para-aortic lymph nodes in pancreatic ductal adenocarcinoma: A retrospective obse… DOI 10.1097/md.0000000000012370↗
- Ren Lang · 1 shared paper, 2021 · strength 0.17
- Shenming Li · 1 shared paper, 2022 · strength 0.15
- Chenggang Li · 1 shared paper, 2022 · strength 0.15
- Zhuo Shao · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.